Potential Effect of Statins on Mycobacterium tuberculosis Infection

Abstract EN

Tuberculosis is one of the 10 leading causes of death in the world.

The current treatment is based on a combination of antimicrobials administered for six months.

It is essential to find therapeutic agents with which the treatment time can be shortened and strengthen the host immune response against Mycobacterium tuberculosis.

M.

tuberculosis needs cholesterol to infect and survive inside the host, but the progression of the infection depends to a large extent on the capacity of the immune response to contain the infection.

Statins inhibit the synthesis of cholesterol and have pleiotropic effects on the immune system, which have been associated with better results in the treatment of several infectious diseases.

Recently, it has been reported that cells treated with statins are more resistant to M.

tuberculosis infection, and they have even been proposed as adjuvants in the treatment of M.

tuberculosis infection.

The aim of this review is to summarize the immunopathogenesis of tuberculosis and its mechanisms of evasion and to compile the available scientific information on the effect of statins in the treatment of tuberculosis.